(Q46660823)

English

Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer?

scientific article published on 28 June 2011

Statements

Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer? (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit